At the Advances in Genome Biology and Technology meeting, multiple companies unveiled high‑throughput sequencing updates that collectively threaten Illumina’s clinical pricing and capacity leadership. Element Biosciences showed Vitari, Ultima updated the UG 200, Roche priced an Axelios nanopore system, and Complete Genomics re‑entered US markets—each promising cheaper per‑genome costs and higher read outputs. Illumina countered with a NovaSeq X roadmap to boost flow‑cell output and accuracy. Industry speakers warned about supply chain and run‑flexibility issues but said increased competition could accelerate clinical genomics adoption for applications like MRD and population sequencing.